Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Rating Upgraded by Royal Bank Of Canada

Rhythm Pharmaceuticals (NASDAQ:RYTM) was upgraded by analysts at Royal Bank Of Canada to a “moderate buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Other equities research analysts also recently issued reports about the stock. HC Wainwright increased their price objective on shares of Rhythm Pharmaceuticals from $123.00 to $125.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research note on Thursday, January 22nd. UBS Group restated a “buy” rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday, December 17th. Wall Street Zen lowered Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Needham & Company LLC upped their price target on Rhythm Pharmaceuticals from $145.00 to $148.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Rhythm Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $131.50.

Rhythm Pharmaceuticals Stock Down 3.4%

Rhythm Pharmaceuticals stock traded down $3.46 during mid-day trading on Wednesday, reaching $99.70. 453,561 shares of the company’s stock were exchanged, compared to its average volume of 637,885. Rhythm Pharmaceuticals has a twelve month low of $45.90 and a twelve month high of $122.20. The company has a market cap of $6.65 billion, a P/E ratio of -32.16 and a beta of 2.00. The company has a fifty day moving average of $105.69 and a 200-day moving average of $103.23.

Insiders Place Their Bets

In other Rhythm Pharmaceuticals news, insider Pamela J. Cramer sold 3,350 shares of Rhythm Pharmaceuticals stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $111.00, for a total value of $371,850.00. Following the completion of the sale, the insider owned 20,814 shares in the company, valued at $2,310,354. The trade was a 13.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Hunter C. Smith sold 4,385 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $101.26, for a total value of $444,025.10. Following the sale, the chief financial officer owned 110,512 shares in the company, valued at approximately $11,190,445.12. The trade was a 3.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 25,003 shares of company stock valued at $2,589,015. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC grew its holdings in Rhythm Pharmaceuticals by 303.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock valued at $28,000 after purchasing an additional 200 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in Rhythm Pharmaceuticals by 97.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock valued at $29,000 after buying an additional 141 shares during the last quarter. Farther Finance Advisors LLC grew its stake in shares of Rhythm Pharmaceuticals by 1,110.3% during the third quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock valued at $35,000 after acquiring an additional 322 shares in the last quarter. Optiver Holding B.V. increased its position in shares of Rhythm Pharmaceuticals by 65.2% during the third quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock worth $37,000 after acquiring an additional 144 shares during the last quarter. Finally, SBI Securities Co. Ltd. lifted its stake in shares of Rhythm Pharmaceuticals by 73.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock worth $37,000 after acquiring an additional 145 shares in the last quarter.

Rhythm Pharmaceuticals News Summary

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: RBC Capital initiated coverage with an “outperform” rating, bringing fresh institutional attention and a formal buy-style endorsement that can support demand for the stock. Read More.
• Positive Sentiment: Multiple broker updates and higher price targets (Wells Fargo, Citizens, Morgan Stanley, UBS, TD Cowen) reinforce a bullish analyst consensus and raise forward expectations for Imcivree revenue and valuation upside. Read More.
• Positive Sentiment: A Yahoo Finance feature highlights accelerating Imcivree revenue and updated management targets — an operational narrative that supports medium-term revenue growth if execution continues. Read More.
• Neutral Sentiment: Zacks upgraded RYTM from “strong sell” to “hold” and flagged the company as likely to beat upcoming earnings estimates — these items reduce near-term downside perception but are not definitive catalysts until the earnings release. Read More.
• Negative Sentiment: CFO Hunter C. Smith sold multiple parcels of RYTM shares this week (SEC filings show sales ~3,569–4,385 shares at ~\$101 each). Insider sales often trigger short-term selling pressure and investor concern despite being a small percentage of total holdings. Read More.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.